OCUGEN INC. - COMMON STOCK

0,5466

11-марта-25 16:45:00

15 мин. задержка

Акции

-0,0098

-1,76%

Сегодняшний диапазон

0,5170 - 0,5700

ISIN

N/A

Источник

NASDAQ

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

09 окт 2024 06:30:32 Источник Nasdaq GlobeNewswire
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

02 окт 2024 06:30:15 Источник Nasdaq GlobeNewswire
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

24 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

09 сен 2024 06:30:12 Источник Nasdaq GlobeNewswire
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

05 сен 2024 07:00:07 Источник Nasdaq GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 07:30:42 Источник Nasdaq GlobeNewswire
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

28 авг 2024 06:30:32 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

26 авг 2024 07:02:41 Источник Nasdaq GlobeNewswire
Ocugen Provides Business Update with Second Quarter 2024 Financial Results

08 авг 2024 06:45:00 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

05 авг 2024 06:30:33 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

02 авг 2024 15:22:33 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

31 июл 2024 21:15:46 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Proposed Public Offering of Common Stock

31 июл 2024 16:15:04 Источник Nasdaq GlobeNewswire
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

29 июл 2024 07:02:15 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

25 июл 2024 06:30:20 Источник Nasdaq GlobeNewswire
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

21 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

20 июн 2024 06:30:31 Источник Nasdaq GlobeNewswire
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

31 май 2024 08:36:49 Источник Nasdaq GlobeNewswire
Ocugen to Present at BIO International Convention 2024

29 май 2024 07:15:00 Источник Nasdaq GlobeNewswire
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

28 май 2024 07:02:39 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.